Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1979 Feb 3;1(6159):298–300. doi: 10.1136/bmj.1.6159.298

Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours.

N Christophidis, F J Vajda, I Lucas, W J Moon, W J Louis
PMCID: PMC1597710  PMID: 421088

Abstract

An outpatient regimen of oral high-dose methotrexate was studied in 14 patients with solid tumours over 12 months. Detailed pharmacokinetic analysis in five patients showed high oral bioavailability (mean +/- SE of mean 87.6 +/- 1.5%), indicating that with this regimen oral methotrexate was well absorbed and the first-pass effect low. Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml). In all 14 patients the clinical response to oral treatment was comparable to that reported to intravenous administration of high-dose methotrexate used in combination with other cytotoxic drugs. The disease-free interval in cases of adult sarcoma was 7.4 +/- 1.3 months and the relapse rate 29%. Out of four patients with small-cell carcinoma, two showed an objective response to oral treatment. We suggest that oral high-dose methotrexate given in divided doses is a rational alternative to expensive intravenous high-dose methotrexate regimens, but further clinical evaluation is necessary.

Full text

PDF
298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chabner B. A., Young R. C. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973 Aug;52(8):1804–1811. doi: 10.1172/JCI107362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Djerassi I., Rominger C. J., Kim J. S., Turchi J., Suvansri U., Hughes D. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer. 1972 Jul;30(1):22–30. doi: 10.1002/1097-0142(197207)30:1<22::aid-cncr2820300105>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  3. Gilby E. D., Bondy P. K., Morgan R. L., McElwain T. J. Combination chemotherapy for small cell carcinoma of the lung. Cancer. 1977 May;39(5):1959–1966. doi: 10.1002/1097-0142(197705)39:5<1959::aid-cncr2820390508>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  4. Goldman I. D., Gupta V., White J. C., Loftfield S. Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols. Cancer Res. 1976 Jan;36(1):276–279. [PubMed] [Google Scholar]
  5. Henderson E. S., Adamson R. H., Oliverio V. T. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965 Aug;25(7):1018–1024. [PubMed] [Google Scholar]
  6. Hill G. W., Roach M. Outpatient chemotherapy for breast cancer. Br Med J. 1978 Apr 29;1(6120):1140–1140. doi: 10.1136/bmj.1.6120.1140-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972 Dec;30(6):1627–1631. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  8. Myers C. E., Lippman M. E., Elliot H. M., Chabner B. A. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3683–3686. doi: 10.1073/pnas.72.9.3683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pitman S. W., Frei E., 3rd Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep. 1977 Jul;61(4):695–701. [PubMed] [Google Scholar]
  10. Price L. A., Goldie J. H. Outpatient chemotherapy for breast cancer. Br Med J. 1977 Dec 17;2(6102):1603–1604. doi: 10.1136/bmj.2.6102.1603-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stoller R. G., Hande K. R., Jacobs S. A., Rosenberg S. A., Chabner B. A. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977 Sep 22;297(12):630–634. doi: 10.1056/NEJM197709222971203. [DOI] [PubMed] [Google Scholar]
  12. Vincent R. G., Pickren J. W., Fergen T. B., Takita H. Evaluation of methotrexate in the treatment of bronchogenic carcinoma. Cancer. 1975 Sep;36(3):873–880. doi: 10.1002/1097-0142(197509)36:3<873::aid-cncr2820360308>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES